Alnylam to Webcast Presentations at Upcoming November Investor Conferences
November 02 2020 - 4:00PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that management will present
company overviews at the following conferences being held
virtually:
- 29th Annual Credit Suisse Virtual Healthcare Conference on
Monday, November 9, 2020 at 12:30 pm ET
- Stifel 2020 Virtual Healthcare Conference on Monday, November
16, 2020 at 2:00 pm ET
A live audio webcast of each presentation will be available on
the Investors section of the Company’s website at
www.alnylam.com/events. A replay will be available on the Alnylam
website within 48 hours after each event.
About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the
lives of people afflicted with rare genetic, cardio-metabolic,
hepatic infectious, and central nervous system (CNS)/ocular
diseases. Based on Nobel Prize-winning science, RNAi therapeutics
represent a powerful, clinically validated approach for the
treatment of a wide range of severe and debilitating diseases.
Founded in 2002, Alnylam is delivering on a bold vision to turn
scientific possibility into reality, with a robust RNAi
therapeutics platform. Alnylam’s commercial RNAi therapeutic
products are ONPATTRO® (patisiran), approved in the U.S., EU,
Canada, Japan, Brazil, and Switzerland, and GIVLAARI® (givosiran),
approved in the U.S, EU, and Brazil. Alnylam has a deep pipeline of
investigational medicines, including six product candidates that
are in late-stage development. Alnylam is executing on its “Alnylam
2020” strategy of building a multi-product, commercial-stage
biopharmaceutical company with a sustainable pipeline of RNAi-based
medicines to address the needs of patients who have limited or
inadequate treatment options. Alnylam is headquartered in
Cambridge, MA. For more information about our people, science and
pipeline, please visit www.alnylam.com and engage with us on
Twitter at @Alnylam or on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201102005646/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media)
617-682-4340 Josh Brodsky (Investors) 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024